Currently, the WHO-HAEM5 classification recognizes as a definite entity DLBCL/HGBCL with MYC and BCL2 rearrangement (with or without BCL6 rearrangement) [1]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.